SCHOTT Pharma AG & Co KgaA
F:1SXP
SCHOTT Pharma AG & Co KgaA
F:1SXP
Price:
14.02
EUR
-1.13%
Market Closed
Market Cap:
€2.1B
Balance Sheet
Balance Sheet Decomposition
SCHOTT Pharma AG & Co KgaA
SCHOTT Pharma AG & Co KgaA
Balance Sheet Decomposition is not available for
SCHOTT Pharma AG & Co KgaA
SCHOTT Pharma AG & Co KgaA
Balance Sheet
SCHOTT Pharma AG & Co KgaA
SCHOTT Pharma AG & Co KgaA
Currency: EUR
| Sep-2020 | Sep-2021 | Sep-2022 | Sep-2023 | Sep-2024 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|
| Assets | |||||||
| Cash & Cash Equivalents |
19
|
28
|
29
|
24
|
23
|
22
|
|
| Cash |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Cash Equivalents |
18
|
28
|
29
|
24
|
23
|
22
|
|
| Short-Term Investments |
1
|
0
|
2
|
4
|
4
|
5
|
|
| Total Receivables |
153
|
187
|
385
|
285
|
399
|
466
|
|
| Accounts Receivables |
131
|
151
|
199
|
224
|
225
|
281
|
|
| Other Receivables |
23
|
36
|
186
|
61
|
173
|
185
|
|
| Inventory |
63
|
84
|
129
|
139
|
146
|
175
|
|
| Other Current Assets |
3
|
3
|
10
|
16
|
12
|
13
|
|
| Total Current Assets |
239
|
302
|
555
|
468
|
584
|
681
|
|
| PP&E Net |
267
|
334
|
517
|
638
|
723
|
786
|
|
| PP&E Gross |
267
|
334
|
517
|
638
|
723
|
786
|
|
| Accumulated Depreciation |
350
|
375
|
462
|
489
|
536
|
589
|
|
| Intangible Assets |
3
|
2
|
2
|
1
|
1
|
1
|
|
| Goodwill |
28
|
29
|
31
|
29
|
29
|
28
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Long-Term Investments |
50
|
62
|
80
|
79
|
85
|
88
|
|
| Other Long-Term Assets |
10
|
10
|
12
|
15
|
15
|
13
|
|
| Other Assets |
28
|
29
|
31
|
29
|
29
|
28
|
|
| Total Assets |
596
N/A
|
740
+24%
|
1 197
+62%
|
1 232
+3%
|
1 438
+17%
|
1 599
+11%
|
|
| Liabilities | |||||||
| Accounts Payable |
62
|
63
|
100
|
91
|
96
|
104
|
|
| Accrued Liabilities |
35
|
43
|
57
|
64
|
54
|
53
|
|
| Short-Term Debt |
1
|
1
|
2
|
1
|
1
|
1
|
|
| Current Portion of Long-Term Debt |
1
|
1
|
3
|
3
|
5
|
4
|
|
| Other Current Liabilities |
111
|
136
|
161
|
193
|
280
|
292
|
|
| Total Current Liabilities |
210
|
244
|
323
|
351
|
435
|
454
|
|
| Long-Term Debt |
3
|
2
|
71
|
69
|
81
|
79
|
|
| Deferred Income Tax |
8
|
12
|
21
|
25
|
20
|
22
|
|
| Minority Interest |
1
|
2
|
2
|
2
|
2
|
2
|
|
| Other Liabilities |
59
|
62
|
72
|
94
|
113
|
150
|
|
| Total Liabilities |
282
N/A
|
322
+14%
|
489
+52%
|
541
+11%
|
651
+20%
|
707
+9%
|
|
| Equity | |||||||
| Common Stock |
0
|
0
|
26
|
151
|
151
|
151
|
|
| Retained Earnings |
0
|
0
|
131
|
494
|
494
|
0
|
|
| Additional Paid In Capital |
0
|
0
|
0
|
494
|
494
|
494
|
|
| Other Equity |
315
|
418
|
551
|
45
|
142
|
247
|
|
| Total Equity |
315
N/A
|
418
+33%
|
707
+69%
|
690
-2%
|
787
+14%
|
892
+13%
|
|
| Total Liabilities & Equity |
596
N/A
|
740
+24%
|
1 197
+62%
|
1 232
+3%
|
1 438
+17%
|
1 599
+11%
|
|
| Shares Outstanding | |||||||
| Common Shares Outstanding |
151
|
151
|
151
|
151
|
151
|
151
|
|
Switch to:
Switch to:
See Also
Discover More
